For dialysis patients with AFib, a newer blood thinner may provide a safer option

June 29, 2018, University of Michigan

People with irregular heartbeat due to a condition called atrial fibrillation, are often prescribed blood thinners to reduce the risk of blood clots that can cause a stroke. But for those who are also on dialysis for kidney failure, the already-difficult choice of blood thinner can seem like a guessing game without a right answer.

One reason: patients on dialysis are routinely excluded from , which test utility and safety of treatments, says Konstantinos Siontis, M.D., first author of new research in Circulation. Siontis' new observational study is the first to reveal that one anticoagulant, (also known as Eliquis), may be safer for this patient population.

"These are the first data to show that apixaban is potentially safer than warfarin in with atrial fibrillation," says Siontis, who recently completed a cardiovascular fellowship at Michigan Medicine's Frankel Cardiovascular Center. "We found patients on apixaban had a significantly lower risk of major bleeding with no difference in stroke, which is what we try to prevent by prescribing these anticoagulants."

The risk of major bleeding was about 30 percent less for those on apixaban compared to warfarin. The team studied patterns of apixaban use and associated outcomes in more than 25,000 Medicare beneficiaries as a research project undertaken by a team at the United States Renal Data System (USRDS) Coordinating Center, based at the University of Michigan. During the study period, apixaban was increasingly used and about 1 in 4 new blood thinner prescriptions in 2015 were for apixaban.

A complicated calculation

If blood isn't completely pumped out of the heart due to atrial fibrillation, it can pool into clots and cause a stroke, leading clinicians to prescribe to reduce the clotting risk. The anticoagulation landscape for all patients continues to change as new agents, including apixaban, become more popular, while mainstay warfarin (also known as Coumadin) is still widely used in the . Warfarin is difficult to manage, though, and comes with the risk of .

Siontis says there's uncertainty about whether adding dialysis to the mix means an anticoagulant is still a good idea for someone with Afib, given the safety and bleeding concerns. Of the four novel anticoagulants, two (dabigatran/Pradaxa and rivaroxaban/Xarelto) have already been associated with higher bleeding rates in dialysis patients compared to warfarin, leaving researchers to focus mainly on apixaban in their push to come up with an alternative, safer anticoagulation plan for these patients.

"Atrial fibrillation is a pretty significant determinant of adverse outcomes in this population," Siontis says. "It's a common problem in dialysis patients who generally have a lot of comorbidities. And the patients on dialysis who have Afib experience higher rates of stroke compared to patients with Afib who aren't on dialysis."

Need for more data

Although clinical trials have investigated use and outcomes of anticoagulants in atrial fibrillation, the most common form of heart arrhythmia, their findings cannot be applied to people on dialysis in the same way as other patients. Siontis says the comorbidities and other worse outcomes associated with kidney failure and dialysis lead most researchers to exclude this population from clinical trials.

"Patients on dialysis are one of the most challenging populations, because they have many comorbid conditions, are often on many prescription drugs and are at significant risk of associated and treatment-related adverse events," says senior co-author Rajiv Saran, M.D., a nephrologist at Michigan Medicine and director of the USRDS Coordinating Center at U-M. "Dialysis patients were excluded from all randomized trials that established the utility of the newer anticoagulants including apixaban."

In the general population, apixaban has been used safely and widely, Siontis says.

"It's one of the agents that's been successful in the general population, but we know very little about dialysis patients specifically," he says, despite FDA approval of updated labeling for apixaban in dialysis patients.

Bridge to randomized trial data

Siontis says these clinical outcomes data, while important, are only the first step.

"It's useful for clinicians to have this information now as we are waiting for the results of important randomized trials that are underway and compare warfarin to apixaban in dialysis patients," Siontis says. "The combination of with is a difficult one, but as we learn more from real-world data and clinical trials, we are hopeful that the decision-making will be better informed in the near future to the benefit of these .

Explore further: Reduced dose of warfarin alternative may help prevent strokes in dialysis patients

More information: Konstantinos C. Siontis et al, Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States, Circulation (2018). DOI: 10.1161/CIRCULATIONAHA.118.035418

Related Stories

Reduced dose of warfarin alternative may help prevent strokes in dialysis patients

March 16, 2017
New research suggests that an alternative to warfarin, when given at a low dose to dialysis patients, can be maintained in the blood at safe levels for potentially preventing strokes. The findings, which appear in an upcoming ...

Interruption of apixaban doesn't impact bleeding in A-fib

December 21, 2017
(HealthDay)—For patients undergoing catheter ablation for nonvalvular atrial fibrillation (AF), both uninterrupted and minimally interrupted apixaban are associated with a very low rate of thromboembolic events, according ...

Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation

March 20, 2018
Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 trial presented today in a late-breaking trial session at EHRA 2018, a European Society of ...

Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion

August 28, 2017
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented ...

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Apixaban superior to warfarin across range of patient risk scores

October 1, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...

Recommended for you

No sweat required: Team finds hypertension treatment that mimics effect of exercise

October 16, 2018
Couch potatoes rejoice—there might be a way to get the blood pressure lowering benefits of exercise in pill form.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Why heart contractions are weaker in those with hypertrophic cardiomyopathy

October 16, 2018
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and affects an estimated 1 in 500 ...

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.